Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. A bifunctional PROTAC molecule consists of a ligand (mostly small-molecule inhibitor) of the protein of interest (POI) and a covalently linked ligand of an E3 ubiquitin ligase (E3)....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hematology and oncology Jg. 13; H. 1; S. 50 - 14
Hauptverfasser:	Li, Xin, Song, Yongcheng
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 13.05.2020 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Animals Antineoplastic agents Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast cancer Cancer Cancer Research Cancer therapies Cancer therapy Cancer treatment Cell growth Clinical trials Degradation Drug Discovery Drug dosages Gene expression Health aspects Hematological malignancies Hematology Humans Leukemia Ligands Ligases Lymphoma Medicine Medicine & Public Health Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - metabolism Nucleic acids Oncology Pharmacodynamics Pharmacokinetics PROTAC Proteasomes Proteins Proteolysis Proteolysis - drug effects Review RNA polymerase Targeted protein degradation Technology application Therapeutic targets Ubiquitin Ubiquitin-protein ligase Ubiquitination Ubiquitination - drug effects PROTAC Targeted protein degradation Cancer therapy Hematological malignancies
ISSN:	1756-8722, 1756-8722
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!